GlassScriptPhysician profile
Van T Huynh
NPI 1538462080
$36,780.51
in general payments reported to CMS, 2019-2025
14 companies · $2,025 in 2025
The $2,025 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,407 · 2020: $9,048 · 2021: $2,727 · 2022: $5,220 · 2023: $11K · 2024: $1,832 · 2025: $2,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,846 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,120 · Food and Beverage: $1,208 · Travel and Lodging: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,846.39 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,120.00 |
| Food and Beverage | $1,207.86 |
| Travel and Lodging | $1,204.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $12,294.01 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $10,413.32 | 2019-2025 | |
| Amgen INC. | $9,414.96 | 2019-2025 | Blincyto, Kyprolis, Blincyto |
| Kite Pharma, INC. | $2,890.00 | 2020 | |
| Adaptive Biotechnologies Corporation | $1,461.02 | 2024-2025 | Clonoseq |
| Novartis Pharmaceuticals Corporation | $205.74 | 2022-2023 | |
| Sobi, INC | $38.27 | 2024 | |
| Azurity Pharmaceuticals, INC. | $26.67 | 2023 | Xatmep |
| Alexion Pharmaceuticals, INC. | $22.57 | 2022 | |
| Btg International INC. | $13.95 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Huynh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.